QUANTITY
​
QUALITY
We’ve created a better database of healthcare M&A data for PE firms, health systems, investment bankers, valuators, attorneys, and dealmakers of all kinds.
HEALTHCARE M&A DATA THAT EXCELS
Click through for more segments
1,300+
Healthcare services transactions since 2010 with reliable deal values and multiples, conveniently categorized by segment and type
QUALITY INFORMATION IS GOOD FOR YOU
There’s more publicly-available private market data with reliable deal values and multiples in healthcare than any other industry, it just takes a heavy lift to find it. We maintain a database of links to our sources, which include:
​
• Fairness opinions
• SEC filings
• Press releases
• Bond market research
• Medicare cost reports
• CON filings (FOIA)
• Form 990s
• Public financial statements
• AG reports
• Insurance department filings
​

ACCURATE
DATA
SIMPLE
FORMAT
AMPLE
DETAIL
RELIABLE
SOURCES
MORE DATA, MORE POSSIBILITES
What could your team do with better market data?

CHOOSE YOUR TREATMENT PLAN
ANATOMY OF OUR ANALYSIS
Ensure deal value is accurately stated on a total invested capital basis
​Source reliable indications of revenue and EBITDA
Share the resulting
data in an easy to use format with links to sources
U.S. Renal Care
-
In February 2019 a group of private equity sponsors agreed to a leveraged buyout of U.S. Renal Care for a total valuation of $2.7b, according to Moody's​​
​
-
U.S. Renal Care’s FY 2018 financial statements, including adjusted EBITDA (less payments to minority investors in subsidiaries) were disclosed publicly in a New York certificate of need filing​​
Enterprise Value: $2.7b
Revenue Multiple: 2.0x
EBITDA Multiple: 9.3x

WE SUPPORT IMPROVED OUTCOMES
SEE FOR YOURSELF
Scope Research was created by Will Hamilton, a healthcare valuation expert who long suffered from a lack of publicly available healthcare transaction data. Our demos are low pressure, customized, and interactive so you always see what you need to see in the time that you have.
